NeuroSpectrum Insights, which is developing a medical device for diagnosing neurological and neurodevelopmental disorders, announced terms for its IPO on Tuesday.
The Bedminster, NJ-based company plans to raise $17 million by offering 3.8 million shares at a price range of $4 to $5.
NeuroSpectrum Insights is a medical device company developing computerized analysis technology that enhances clinicians' capabilities in diagnosing neurological and neurodevelopmental disorders. The company's first product, GyriCalc, is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated analysis of MRI images. NeuroSpectrum Insights has not generated any revenues to date.
NeuroSpectrum Insights was founded in 2016. It plans to list on the NYSE under the symbol NSIH. Network 1 Financial Securities is the sole bookrunner on the deal.
